主要终点指标是总体生存期。
结论：在四种不同类型的肿瘤中，IGS和无转移生存期以及总体生存期紧密相关。
Conclusions The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors.
虽然这项工作非常关键，但它仅涵盖了整个门户生存期中所需的总体规划工作的一部分。
Although this work is critical, it covers only a portion of the total planning effort required over the lifetime of a portal.
所有患者的疾病仅占总体时间为13个月，但是，那些只有肿瘤组织中存在变异的患者的生存期要长于那些肿瘤组织和血浆中均存在变异的患者。
Overall time to progression for all patients was 13 months, but it was longer in patients with tumor-only mutations than in those with tumor and serum mutations.
结论：我们对边缘区淋巴瘤的研究是已报道的研究中规模最大的之一，结论是边缘区淋巴瘤总体预后良好，中位总生存期超过19年。
Conclusions: In our MZL series, one of the largest reported, prognosis of MZL is good with a median OS of over 19 years.
患者接受了三种不同治疗方案，平均生存期10个月，三年内总体生存率是27%。
With patients receiving the three different treatments, average survival was 10 months with a 27% overall survival rate at three years.
患者接受了三种不同治疗方案，平均生存期10个月，三年内总体生存率是27%。
With patients receiving the three different treatments, average survival was 10 months with a 27% overall survival rate at three years.
应用推荐